SCHEMBL856829

SCHEMBL856829

Cc1ncnc(N2CCOc3ccc(-c4ccc(C(=O)O)cc4)cc3C2)c1Cc1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 5/20 0.41
PIK3CA P42336 12/20 0.39
RIPK1 Q13546 1/20 0.35
CREBBP Q92793 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857097 0.93 GPR142 (0.41) GPR142PIK3CARIPK1CREBBP
SCHEMBL858637 0.93 GPR142 (0.41) GPR142PIK3CARIPK1CREBBP
SCHEMBL858885 0.92 GPR142 (0.42) GPR142PIK3CARIPK1CREBBP
Hydrochloric Acid SCHEMBL3754891 0.91 GPR142 (0.41) GPR142PIK3CARIPK1CREBBP
SCHEMBL856409 0.91 GPR142 (0.41) GPR142PIK3CARIPK1CREBBP
SCHEMBL3805766 0.89 GPR142 (0.38) GPR142PIK3CARIPK1
SCHEMBL856044 0.89 HTR2A (0.41) GPR142
SCHEMBL3806500 0.89 ALDH1A1 (0.41) GPR142
SCHEMBL3811900 0.88 ULK1 (0.40) GPR142PIK3CA
Hydrochloric Acid SCHEMBL3801651 0.88 ALDH1A1 (0.40) GPR142

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
WO-2010135568-A1 BENZOXAZEPINES AS INHIBITORS OF MTOR AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-11-25 WO disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GPR142 1660/4885PIK3CA 3/4885RIPK1 1300/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GPR142 2004/4885PIK3CA 3/4885RIPK1 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.